Stoke Therapeutics, Inc. (STOK) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary presents a mixed picture: a strong 25% YoY revenue growth and a slight improvement in net loss, but increased R&D expenses and a decrease in cash reserves. The absence of strategic updates, risk assessments, or return plans leaves uncertainty. Without additional insights from the Q&A or market cap data, the positive revenue is offset by financial and strategic uncertainties, resulting in a neutral outlook for the stock price over the next two weeks.
Key Financial Performance
Revenue Stoke Therapeutics reported revenue of $12.5 million for Q1 2026, representing a 25% increase year-over-year. This growth was primarily driven by increased sales of their lead therapeutic candidate.
Research and Development Expenses R&D expenses were $18.3 million, up 15% compared to the same period last year. The increase was attributed to expanded clinical trial activities and higher personnel costs.
Net Loss The company reported a net loss of $10.8 million, which is a 5% improvement year-over-year. This was due to higher revenue offsetting increased expenses.
Cash and Cash Equivalents Stoke Therapeutics ended the quarter with $150 million in cash and cash equivalents, down 10% from the previous year. The decrease was due to ongoing investments in R&D and operational activities.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Adam Ferrari
BTIG LLC
CEO Director
Canaccord Genuity
Cantor Fitzgerald
Chase Co
Chico Wedbush
Chief Executive
Chief Financial
Chief Medical
Chief Patient
Co Research
Conference Instructions
Corp Research
Cowen Research
Cox Jefferies
Financial Officer
LLC Research
Medical Officer
Officer Chief
Patient Officer
Research Division
Securities
Stoke Therapeutics
conference Chief
statement
today
STOK Slides
STOK Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
